Immunohistochemical Localization of Fibroblast Activation Protein in Coronary Arteries with Different Forms of Atherosclerosis

Figures

• 

  Figure 1. Sections from human coronary artery (5× magnification) from patient with dilated cardiomyopathy with no atherosclerotic plaque after H&E staining (left). Staining with F19 mouse anti-human FAP antibody as primary antibody and biotinylated anti-mouse IgG as secondary antibody (right). Section from coronary artery with no atherosclerosis shows no staining with F19 (black arrow).

• 

  Figure 2. Sections from human coronary artery with mild atherosclerosis (5× and 20× magnifications). Staining with F19 mouse anti-human FAP antibody as primary antibody and biotinylated anti-mouse IgG as secondary antibody (left). Negative control with staining with biotinylated anti-mouse IgG (right). Weak F19 staining in coronary lesions with mild atherosclerosis (black arrow) compared with negative control (blue arrow).

• 

  Figure 3. Sections from human coronary artery with severe atherosclerotic plaque (5× magnification). Staining with F19 mouse anti-human FAP antibody as primary antibody and biotinylated anti-mouse IgG as secondary antibody (left). Negative control with staining with biotinylated anti-mouse IgG (right). Strongly positive F19 staining in advanced atherosclerotic plaque (black arrow) compared with no F19 staining in negative control (blue arrow).

• 

  Figure 4. Sections from a human coronary artery with severe atherosclerotic plaque (5×, 10×, and 20× magnification). Staining with an F19 mouse anti-human FAP antibody as the primary antibody and biotinylated anti-mouse IgG as the secondary antibody. Strongly positive F19 staining is localized in the core of the advanced atherosclerotic plaque (black arrow).

• 

  Figure 5. Sections from post bypass atherosclerosis (5× and 10× magnifications). Staining with F19 mouse anti-human FAP antibody as primary antibody and biotinylated anti-mouse IgG as secondary antibody (left). Negative control with staining with biotinylated anti-mouse IgG (right). Diffuse pattern of F19 staining in sections from post bypass atherosclerosis (black arrow) compared with negative control (blue arrow).

• 

  Figure 6. Sections from post-heart transplant arteriosclerosis (5× and 10× magnification). Staining with F19 mouse anti-human FAP antibody as primary antibody and biotinylated anti-mouse IgG as secondary antibody (left). Negative control with staining with biotinylated anti-mouse IgG (right). Strongly positive diffuse pattern of F19 staining in sections from post-heart transplant arteriosclerosis (black arrow) compared with negative control (blue arrow).

• 

  Figure 7. Comparison of the F19 (anti-human FAP Ab) staining of advanced and moderate native coronary atherosclerotic plague, vein graft arteriosclerosis lesion, and post-heart transplant arteriosclerosis (20× magnification). (A,B) The localization of the most prominent F19 staining in the coronary plaques in native coronary disease (black arrows). (C,D) The strongly positive diffuse pattern of F19 staining in the tunica intima and media of the heart transplant arteriosclerosis (black arrow) and diffuse pattern of F19 staining in the tunica intima of the vein graft atherosclerosis (black arrow).